Center-Authored Papers

Filters: Author is Chiorean, E Gabriela  [Clear All Filters]
2017
Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C et al..  2017.  Pancreatic Adenocarcinoma, Version 2.2017. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK. 15(8):1028+. Abstract
Kim R, Chiorean GE, Amin M, Rocha-Lima CMS, Gandhi J, Harris WP, Song T, Portnoy D.  2017.  Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment.. British journal of cancer. Abstract
LoRusso PM, Gounder M, Jalal SI, André V, Kambhampati SRP, Loizos N, Hall J, Holzer TR, Nasir A, Cosaert J et al..  2017.  Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.. Investigational new drugs. Abstract
Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean GE, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS et al..  2017.  Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2016715292. Abstract
2016
Saif MW, Knost JA, Chiorean GE, Kambhampati SRP, Yu D, Pytowski B, Qin A, Kauh JS, O'Neil BH.  2016.  Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer.. Cancer chemotherapy and pharmacology. 78(4):815-824. Abstract
McCormick KA, Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean GE.  2016.  Pancreatic cancer: Update on Immunotherapies and Algenpantucel-L.. Human vaccines & immunotherapeutics. 12(3):563-575. Abstract
Chiorean GE, Von Hoff DD, Tabernero J, El-Maraghi R, Ma WW, Reni M, Harris M, Whorf R, Liu H, Li JS et al..  2016.  Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.. British journal of cancer. Abstract
Chiorean GE, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR et al..  2016.  CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with metastatic pancreatic cancer.. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. Abstract
Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean GE.  2016.  Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.. Immunotherapy. Abstract
Deng L, Gu H, Zhu J, Nagana Gowda GA, Djukovic D, Chiorean GE, Raftery D.  2016.  Combining NMR and LC/MS Using Backward Variable Elimination: Metabolomics Analysis of Colorectal Cancer, Polyps, and Healthy Controls.. Analytical chemistry. 88(16):7975-83. Abstract
Coveler AL, Herman JM, Simeone DM, Chiorean GE.  2016.  Localized Pancreatic Cancer: Multidisciplinary Management.. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 35:e217-26. Abstract
2015
Zhu J, Djukovic D, Deng L, Gu H, Himmati F, Abu Zaid M, Chiorean GE, Raftery D.  2015.  Targeted serum metabolite profiling and sequential metabolite ratio analysis for colorectal cancer progression monitoring.. Analytical and bioanalytical chemistry. Abstract
Chen C, Deng L, Wei S, Nagana Gowda GA, Gu H, Chiorean GE, Abu Zaid M, Harrison ML, Pekny JF, Loehrer PJ et al..  2015.  Exploring Metabolic Profile Differences between Colorectal Polyp Patients and Controls Using Seemingly Unrelated Regression.. Journal of proteome research. Abstract
Chiorean GE, Hurwitz HI, Cohen RB, Schwartz JD, Dalal RP, Fox FE, Gao L, Sweeney CJ.  2015.  Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. Abstract
Chiorean GE, LoRusso P, Strother RM, Diamond JR, Younger A, Messersmith WA, Adriaens L, Liu L, Kao RJ, DiCioccio AT et al..  2015.  A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Tabernero J, Chiorean GE, Infante JR, Hingorani SR, Ganju V, Weekes C, Scheithauer W, Ramanathan RK, Goldstein D, Penenberg DN et al..  2015.  Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.. The oncologist. 20(2):143-50. Abstract
Gu H, Du J, Neto FC, Carroll PA, Turner SJ, Chiorean GE, Eisenman RN, Raftery D.  2015.  Metabolomics method to comprehensively analyze amino acids in different domains.. The Analyst. 140(8):2726-34. Abstract
2014
Chiorean GE, Sweeney C, Youssoufian H, Qin A, Dontabhaktuni A, Loizos N, Nippgen J, Amato R.  2014.  A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors.. Cancer chemotherapy and pharmacology. Abstract
Chiorean GE, Von Hoff DD.  2014.  Taxanes: impact on pancreatic cancer.. Anti-cancer drugs. Abstract
LoRusso P, Venkatakrishnan K, Chiorean GE, Noe D, Wu J-T, Sankoh S, Corvez M, Sausville EA.  2014.  Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2.. Investigational new drugs. 32(1):160-70. Abstract
Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean GE, Chung V, Cohen SJ, Czito B, Engebretson A et al..  2014.  Pancreatic adenocarcinoma, version 2.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(8):1083-93. Abstract
Chiorean GE, Schneider BP, Akisik FM, Perkins SM, Anderson S, Johnson CS, Dewitt J, Helft P, Clark R, Johnston EL et al..  2014.  Phase 1 Pharmacogenetic and Pharmacodynamic Study of Sorafenib With Concurrent Radiation Therapy and Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer.. International journal of radiation oncology, biology, physics. Abstract
Hocevar BA, Kamendulis LM, Pu X, Perkins SM, Wang Z-Y, Johnston EL, Dewitt JM, Li L, Loehrer PJ, Klaunig JE et al..  2014.  Contribution of environment and genetics to pancreatic cancer susceptibility.. PloS one. 9(3):e90052. Abstract